Abstract

Objective To evaluate the value of CYFRA21-1 examination in the detection of urothelial carcinoma (UC).Methods Serum concentrations of CYFRA21-1 were examined by electrochemiluminescence technique in 65 cases with UC,61 cases of non-UC patients (including 21 cases of renal carcinoma,20 cases of benign prostatic hyperplasia,10 cases of prostatic carcinoma,10 cases of urolithiasis) and 43 hea]thy individuals.Sixty-five UC cases including 9 renal pelvis UC cases,4 ureter UC cases,52 bladder UC cases,61 non-UC cases including 21 renal carcinoma cases,20 benign prostatic hyperplasia cases,10 prostatic carcinoma cases,10 urolithasis cases.Results The serum CYFRA21-1 concentration in UC patients (7.57± 12.76) μg/L was significantly higher than the healthy controls (2.58±0.97) μg/L and also the non-UC patients (2.75± 1.34) μg/L (P<0.01).The difference between the healthy individuals and the nonUC patients was not significant (P>0.05).According to the manual in the reagent kit,the positive value of serum CYFRA21-1 was defined as greater than 3.3 μg/L.The false positive rate in healthy controls and the non-UC patients was 10%-30%.The positive percentage of serum CYFRA21-1 of the 65 UC patients was 67.7% (44/65).In low,middle and high grade UC cases,the positive rates were 50.0% (10/20),62.5% (5/8) and 78.3% (29/37) respectively.The difference of the positive rates between the high grade group and middle,low grade groups was significant (x2 =4.55,P<0.05).The positive rates in non-muscle invasive (Ta-Ti) UC and in healthy controls were 40.9% (9/22) and 23.2% (10/43) respectively,and the difference between the two groups was not significant (x2=2.19,P>0.05).The positive rate in muscle invasive (T2-T3) UC was 78.6% (22/28) and the difference compared with healthy controls was significant (x2=20.96,P<0.01).The positive rate in local advanced and metastatic UC (>T3) was 86.7% (13/15).The positive rates were not significantly deferent between the T2-T3 group and the > T3 group (x2 =1.97,P>0.05).Conclusions The serum CYFRA21-1 positive rate is 67.7% in UC patients,which was higher than non-UC patients and healthy controls,and associated positively with the pathologic grade and the clinical stage of UC.Monitoring the serum CYFRA21-1 is effective in assessing the outcomes and prognosis of UC,if the serum CYFRA21-1 was positive.The serum CYFRA21-1 test has some significance in distinguishing UC from renal carcinoma and prostatic carcinoma. Key words: Urothelium; Carcinoma; Tumor markers; Keratins

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call